Annals of Oncology - McMaster Experts

publication venue for

316P First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study 2023
521P Deciphering a three-miRNA signature as a prognostic biomarker in glioma patients: Correlation with DFS and OS 2023
The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC) 2022
1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC) 2022
1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial 2022
1748P 4-factor model to predict response and survival benefit with durvalumab (D) in previously treated metastatic urinary tract carcinoma (mUTC) 2022
780TiP A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies 2022
CN76 Cost effectiveness of high versus low-to-moderate intensity exercise during oncological treatment: The Phys-Can RCT 2022
196P An international consensus on actions to improve lung cancer survival: A clinical review by the international cancer benchmarking partnership (ICBP) 2022
114TiP KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) 2021
LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) 2021
5P Uncovering the evolution of glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers 2020
1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1) 2020
1195P The value of detecting resistance through liquid biopsy 2020
1816MO ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of carboplatin-based chemotherapy – with a focus on nausea. MASCC Antiemetic Study Group survey 2020
919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut) 2020
LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) 2020
LBA87 A pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer (AToM) 2020
Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC) 2019
Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC) 2019
CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC) 2019
CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC) 2019
Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG) 2019
Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC) 2019
Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC) 2019
Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model 2019
FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) 2019
Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy 2019
Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND226 study of durvalumab +/- tremelimumab in combination with platinum-doublet chemotherapy 2019
Prescription and treatment patterns of lenvatinib (L) in patients with radioactive iodine-refractory differentiated thyroid cancer (rDTC): A retrospective analysis of the Canadian Patient Support Program (PSP) 2019
Prescription and treatment patterns of lenvatinib (L) in patients with radioactive iodine-refractory differentiated thyroid cancer (rDTC): A retrospective analysis of the Canadian Patient Support Program (PSP) 2019
Serum netrin-1 as a biomarker for colorectal cancer detection 2019
Tobacco retail access and tobacco cessation among head and neck cancer (HNC) survivors 2019
A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases 2019
Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice 2019
A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC) 2018
A systematic approach to smoking cessation in regional cancer centres in Ontario, Canada 2018
Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC) 2018
Awareness of the cancer and non-cancer related harms of continued smoking in cancer survivors 2018
How advanced lung cancer patients are really treated at the population level? The Ontario, Canada experience 2018
The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review 2018
Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26 2017
Increasing palliative interventions at the end of life: patterns in metastatic colorectal cancer (mCRC) 2017
Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC) 2017
Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC) 2017
Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population 2017
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data 2017
Stereotactic ablative radiotherapy (SABR) for oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) during abiraterone therapy: A phase I study 2017
A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer 2017
A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI) 2016
Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: Ontario Clinical Oncology Group DOVE trial 2016
Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers 2016
Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC) 2016
Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC) 2016
NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC 2016
Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis 2016
Prognostic ability of HR-QoL parameters in metastatic renal cell carcinoma (mRCC) 2016
Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) – a validation study 2016
Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience 2016
Safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving breast cancer resistant protein (BCRP) substrate chemotherapy agents 2016
genitourinary tumours, prostate Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC) 2016
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers 2016
Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis 2015
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state 2015
Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc) 2014
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck 2013
A PHASE I STUDY OF THE COMBINATION OF RO4929097 (RO) AND CEDIRANIB (CD) IN PATIENTS WITH ADVANCED SOLID TUMORS (PJC-004/NCI 8503) 2012
A PHASE IB COMBINATION STUDY OF RO4929097 (RO), A GAMMA-SECRETASE INHIBITOR, AND TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS 2012
A Phase I Study of the Combination of RO4929097 (RO) And Cediranib (CD) in Patients with Advanced Solid Tumors (PJC-004/NCI 8503) 2012
A Phase IB Combination Study of RO4929097 (RO), A Gamma-Secretase Inhibitor, and Temsirolimus (TEM) in Patients (PTS) with Advanced Solid Tumors 2012
A RANDOMIZED PHASE II STUDY OF OGX-427 PLUS PREDNISONE (P) VS. P ALONE IN PATIENTS (PTS) WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (CRPC) 2012
A Randomized Phase II Study of OGX-427 Plus Prednisone (P) Vs. P Alone in Patients (PTS) with Metastatic Castration Resistant Prostate Cancer (CRPC) 2012
ASSOCIATION OF PROGRESSION BY PROSTATE CANCER WORKING GROUP (PCWG)-2 CRITERIA AND SURVIVAL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER 2012
LONG-TERM EFFICACY AND SAFETY OF L-BLP25 VACCINE IN A MULTI-CENTRE OPEN-LABEL STUDY OF PATIENTS WITH UNRESECTABLE STAGE III NSCLC 2012
MIR-99A/LET7C/MIR-125B SIGNATURE TO PREDICT SENSITIVITY TO ANTI-EGFR MONOCLONAL ANTIBODIES IN METASTATIC COLORECTAL CANCER (MCRC) 2012
PROGNOSTIC STRATIFICATION OF ADVANCED UROTHELIAL CARCINOMA (UC) RECEIVING SECOND-LINE SYSTEMIC THERAPY INCLUDING TIME FROM PRIOR CHEMOTHERAPY (TFPC) AS A PROGNOSTIC FACTOR 2012
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC 2012
CDX2 VDR POLYMORPHISM IMPINGES ON THE RESPONSE OF CULTURED BREAST CANCER CELL LINES TO VITAMIN D 2012
LUNG TUMORS TO BRAIN METASTASES: DO MICRORNAS PLAY A PROGNOSTIC ROLE? 2012
MICRORNA PROFILING AS A POTENTIAL PREDICTIVE TOOL OF GIANT CELL TUMOR EVOLVING IN HIGH GRADE OSTEOSARCOMA: A CASE REPORT 2012
MICRORNA PROFILING IN GASTRIC CANCER 2012
PATIENT FACTORS INVOLVED IN REFERRAL FOR LYNCH SYNDROME 2012
SUBCUTANEOUS ADMINISTRATION OF A THROMBOSPONDIN-1 MIMETIC PEPTIDE NORMALIZES TUMOR VASCULATURE, INCREASES DRUG UPTAKE AND INDUCES REGRESSION OF ADVANCED OVARIAN CANCER 2012
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a 2012
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. 2012
AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR TRANSFORMED INDOLENT NON-HODGKIN LYMPHOMA: A REPORT OF THE CANADIAN BLOOD AND MARROW TRANSPLANT GROUP (CBMTG) 2011
IMPROVED 6-MONTH SURVIVAL RATE IN SUBJECTS WITH PROSTATE STEM CELL ANTIGEN POSITIVE TUMORS IN A GLOBAL, RANDOMIZED PHASE 2 TRIAL COMPARING GEMCITABINE VS. GEMCITABINE + AGS-1C4D4 (ASP6182) IN METASTATIC PANCREATIC CANCER 2011
COMBINING PROTEIN INTERACTION AND GENE PROFILING METHODS FOR PREDICTING LAPATINIB RESPONSE 2011
A MULTI-INSTITUTIONAL PHASE II STUDY OF SINGLE AGENT ABI-007 IN PLATINUM REFRACTORY UROTHELIAL CARCINOMA 2010
A SYSTEMATIC REVIEW AND CONSENSUS RECOMMENDATIONS ON THE USE OF BIOMARKERS IN THE TREATMENT OF NON-SMALL CELL LUNG CARCINOMA (NSCLC) 2010
HIGH INCONSISTENCIES AMONG LISTS OF CAUTIONED and PROHIBITED DRUGS IN ONCOLOGY PHASE 1 AND PHASE 2 TRIALS 2010
CISPLATIN DOSE INTENSITY CORRELATES WITH OUTCOME IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA RECEIVING CONCURRENT CISPLATIN BASED CHEMORADIATION: A MULTI-INSTITUTIONAL EXPERIENCE 2009
NOVEL OPTICAL PROTEOMICS MOLECULARLY PROFILES BREAST CANCER PATIENTS LEADING TO INDIVIDUALISED PROGNOSIS AND TAILORED TREATMENT 2009
A PHASE 2 STUDY OF PATUPILONE IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (HRPC) WHO HAVE PROGRESSED AFTER DOCETAXEL 2008
EFFECTS OF ZOLEDRONIC ACID (ZOL) ON SURVIVAL IN PATIENTS WITH METASTATIC BONE DISEASE AND HIGH BONE TURNOVER: RESULTS FROM A META-ANALYSIS 2008
RANDOMIZED, DOUBLE-BLIND PHASE II TRIAL OF CARBOPLATIN plus PACLITAXEL [C plus P] WITH EITHER DAILY ORAL CEDIRANIB, AN INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR [VEGFR] TYROSINE KINASES, OR PLACEBO, IN ADVANCED NON-SMALL CELL LUNG CANCER [NSCLC]: A STUDY OF THE NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP 2008
RISK FACTORS FOR SKELETAL-RELATED EVENT (SRES) IN ZOLEDRONIC ACID-TREATED PATIENTS WITH BONE METASTASES (METS) FROM NON-SMALL CELL LUNG CANCER (NSCLC) 2008
THE PROGNOSTIC VALUE OF PAIN SCORES FOR CLINICAL OUTCOMES IN ADVANCED BREAST CANCER (BC), PROSTATE CANCER (PC), AND OTHER SOLID TUMORS (OST) 2008
Prognostic factors in advanced-stage pediatric anaplastic large cell lymphoma (ALCL): Analysis of patients from two consecutive pediatric oncology group (POG) studies 2008
Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006 2008
Phase II pilot study on brachytherapy with ECF vs brachytherapy and standard chemoradiation in esophageal cancer 2007
A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS 2006
A multicenter phase II study of lapatinib in recurrent or metastatic adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT) 2006
A phase II study of ispinesib in patients (PTS) with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC) 2006
Mechanisms of cognitive function and fatigue: A prospective, longitudinal cohort study in colorectal cancer patients 2006
Phase I clinical trials referrals and enrollment: Five-year experience at the Princess Margaret Hospital 2006
Phase II study of bay 43-9006 (SORAFENIB) in patients with chemo-naive hormone refractory prostate cancer (HRPC) 2006
Prognostic significance of persistently elevated N-telopeptide levels in patients with bone metastases from solid tumors 2006
The role of patient values in evidence-based medicine (EBM) and its application to treatment decision-making between oncologists and women with breast cancer 2006
Zoledronic acid may improve survival in lung cancer patients with high baseline bone marker levels 2006
A phase II trial of oblimersen sodium (G3139) plus rituximab for treatment of patients with recurrent B-cell non-Hodgkin's lymphoma 2005
A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma 2005
The impact of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of anticancer agents, as perceived by patients, physicians and institution review board members (IRBs) 2005
Use of venous access devices in patients younger than 21 years of age 2005
Final analysis of a randomized phase I study of the C-RAF kinase inhibitor BAY 43-9006 in patients with acute myeloid leukemia 2004
Zoledronic acid reduces the risk of skeletal complications in patients with malignant bone disease: evidence from 3 different multiple event analysis models 2004
Zoledronic acid reduces the survival-adjusted cumulative incidence of radiotherapy to bone in patients with bone metastases from breast or prostate cancer 2004
Pharmacologic insights into the future of trastuzumab. 2001
NCICCTG OV12: An international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/paclitaxel plus platinum containing chemotherapy (CT). 2000
Phase II study of pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HHC). 2000
Phase III study of zoledronic acid versus pamidronate in patients with metastatic bone lesions due to breast cancer or multiple myeloma: Preliminary results. 2000
Clinical and pharmacokinetic (PK) results of 4 phase I studies of the second generation matrix metalloprotease (MMP) inhibitor Bay 12-9566, a non-peptidic biphenyl inhibitor of MMPs 2, 3&9 1998
Phase I study of the matrix metalloprotease inhibitor (MMPI) BAY 12-9566 in patients with advanced cancer 1998
Phase I trial of the bombesin receptor antagonist RC-3095 in patients with refractory solid tumors 1998
Phase I trial of the bombesin receptor antagonist RC-3095 in patients with refractory solid tumors 1998
Planned and completed NCIC CTG trials with BAY 12-9566, a novel metalloprotease inhibitor (MMPI) 1998
1641P Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects. 35:s990. 2024
1890P End-of-Life (EOL) systemic anticancer treatment (SACT) and health services use before and during the COVID-19 pandemic. 35:s1104-s1105. 2024
1902P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective. 35:s1109. 2024
LBA37 Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN). 35:s1228. 2024
LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy. 35:s1202. 2024
44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy. 35:S22-S22. 2024
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. 35:448-457. 2024
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. 35:66-76. 2024
1327P First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis). 34:S766-S766. 2023
1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results. 34:S982-S983. 2023
1821P High serum FSH/T ratio as a marker for the development of cardiovascular disease in ADT recipients. 34:S986-S986. 2023
1893P Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC. 34:S1018-S1019. 2023
2361MO Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC) [PET-MUSE]. 34:S1200-S1200. 2023
663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC. 34:S466-S467. 2023
976P Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone. 34:S605-S605. 2023
CN57 Patients, informal caregivers and healthcare professionals experience in adoptive cell therapies: An experience-based co-design study (EBCD-ACT). 34:S1242-S1242. 2023
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial. 34:578-588. 2023
P-418 Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study. 34:S159-S159. 2023
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. 33:1250-1268. 2022
116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis. 33:S591-S592. 2022
138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial. 33:S602-S602. 2022
633P Determining the prognostic value of end of treatment (EOT) 18F-choline positron emission tomography (PET) in patients treated with primary central nervous system lymphoma (PCNSL) who respond to first-line therapy: A single centre retrospective study at the Royal Marsden Hospital (RMH). 33:S832-S832. 2022
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. 32:896-905. 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. 32:757-765. 2021
A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. 31:951-957. 2020
Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study. 30:ix1-ix1. 2019
Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG). 30:v720-v720. 2019
Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model. 30:v651-v652. 2019
FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). 30:v403-v403. 2019
Tobacco retail access and tobacco cessation among head and neck cancer (HNC) survivors. 30:v742-v742. 2019
Corrections to “De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017”. 30:1181-1181. 2019
A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases. 30:iii73-iii73. 2019
Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. 29:2153-2153. 2018
Influenza vaccine effectiveness among cancer patients: A population-based study using health administrative and laboratory testing data from Ontario, Canada. 29:viii568-viii568. 2018
Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. 29:viii340-viii340. 2018
Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database. 29:viii238-viii238. 2018
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. 29:1423-1430. 2018
The next generation of radioimmunotherapy: Targeted alpha therapy (TAT). 29:iii6-iii6. 2018
Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al.. 29:281-282. 2018
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. 28:viii30-viii35. 2017
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC). 28:v314-v315. 2017
Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database. 28:v238-v238. 2017
Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26. 28:v398-v398. 2017
Development of a web-based application using machine learning algorithms to facilitate systematic literature reviews. 28:v518-v518. 2017
Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population. 28:v308-v309. 2017
Stereotactic ablative radiotherapy (SABR) for oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) during abiraterone therapy: A phase I study. 28:v292-v292. 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. 28:1700-1712. 2017
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. 28:1560-1568. 2017
Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. 28:1448-1456. 2017
A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer. 28:i4-i5. 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. 28:702-710. 2017
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. 27:2216-2224. 2016
Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers. 27:vi499-vi499. 2016
Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. 27:1761-1767. 2016
Correction to: Planning and reporting of quality-of-life outcomes in cancer trials. 27:209-209. 2016
Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis. 26:vi55-vi55. 2015
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. 26:1533-1546. 2015
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. 26:1305-1313. 2015
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200. 26:973-981. 2015
Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A. 26:ii3-ii3. 2015
Planning and reporting of quality-of-life outcomes in cancer trials. 26:1966-1973. 2015
Cognitive function and fatigue after diagnosis of colorectal cancer. 25:2404-2412. 2014
Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer. 25:2096-2096. 2014
A Phase 1/2 Study of Ipilimumab in Women with Metastatic or Recurrent Hpv-Related Cervical Carcinoma: a Study of the Princess Margaret and Chicago N01 Consortia. 25:iv324-iv324. 2014
Angiogenic Switch As Predictor of Response to Chemotherapy+ Bevacizumab in Patients with Metastatic Colorectal Cancer. 25:iv181-iv181. 2014
Outcomes with Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma (Uc) Following Previous Perioperative Cisplatin-Based Therapy. 25:iv302-iv302. 2014
Phase 3 (P04832) Trial Results for Rolapitant, a Novel Nk-1 Receptor Antagonist, in the Prevention of Chemotherapy-Induced Nausea and Vomiting (Cinv) in Patients Receiving Cisplatin-Based Chemotherapy. 25:v1-v1. 2014
Phase Ii Study of Individualized Sunitinib As First-Line Therapy for Metastatic Clear Cell Renal Cell Cancer (Mrcc). 25:iv292-iv292. 2014
Pooled Analysis of the Prognostic and Predictive Value of Kras Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer (Nsclc) Treated with Egfr Tkis (E-Tki). 25:iv58-iv58. 2014
Reasons for Delay in Time to Initiation of Adjuvant Chemotherapy for Colon Cancer: a Multi-Institution Study. 25:iv198-iv198. 2014
The Relationship Between Egfr and Kras Mutation Status and Overall Survival (Os) in the Ncic Ctg Br.26 Randomized Trial of Dacomitinib (D) Versus Placebo (P) in Patients with Previously Treated Non Small Cell Lung Cancer (Nsclc). 25:iv462-iv462. 2014
The Significance of Complete Response (Cr) in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma (Uc). 25:iv301-iv301. 2014
Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. 25:992-998. 2014
Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice. 25:791-800. 2014
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. 24:3065-3069. 2013
Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. 24:3082-3088. 2013
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. 24:2972-2977. 2013
Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. 24:2534-2542. 2013
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. 24:1792-1801. 2013
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.. 24:1792-1801. 2013
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. 24:355-361. 2013
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.. 24:355-361. 2013
Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. 23:2977-2982. 2012
Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods.. 23:2977-2982. 2012
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. 23:2613-2619. 2012
Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer. 23:ix297-ix298. 2012
Long-Term Efficacy and Safety of L-BLP25 Vaccine in a Multi-Centre Open-Label Study of Patients with Unresectable Stage III NSCLC. 23:ix395-ix395. 2012
MIR-99A/LET7C/MIR-125B Signature to Predict Sensitivity to Anti-Egfr Monoclonal AntiBodies in Metastatic Colorectal Cancer (MCRC). 23:ix183-ix183. 2012
Prognostic Stratification of Advanced Urothelial Carcinoma (UC) Receiving Second-Line Systemic Therapy Including Time from Prior Chemotherapy (TFPC) as a Prognostic Factor. 23:ix265-ix266. 2012
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. 23:1780-1788. 2012
Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials. 23:1633-1639. 2012
P-0215 Patient Factors Involved in Referral for Lynch Syndrome. 23:iv91-iv91. 2012
P1.20 CDX2 VDR Polymorphism Impinges on the Response of Cultured Breast Cancer Cell Lines to Vitamin D. 23:v17-v18. 2012
P1.21 Microrna Profiling as a Potential Predictive Tool of Giant Cell Tumor Evolving in High Grade Osteosarcoma: A Case Report. 23:v18-v18. 2012
P1.26 Micrornas' Expression Profile and their Correlation with Clinical Outcome in head and Neck Squamous Cell Carcinoma. 23:v19-v20. 2012
P1.27 Lung Tumors to Brain Metastases: Do Micrornas Play a Prognostic Role?. 23:v20-v20. 2012
P3.10 Microrna Profiling in Gastric Cancer. 23:v35-v36. 2012
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. 23:1512-1517. 2012
Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. 23:1646-1651. 2012
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. 23:1185-1189. 2012
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.. 23:1185-1189. 2012
Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). 23:238-244. 2012
Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).. 23:238-244. 2012
Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. 22:2358-2365. 2011
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. 22:2417-2423. 2011
Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. 22:2086-2093. 2011
End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma. 22:910-915. 2011
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. 22:335-340. 2011
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. 21:2220-2226. 2010
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12). 21:283-290. 2010
Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. 21:19-26. 2010
Stopping a trial early in oncology: for patients or for industry?. 20:395-396. 2009
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. 19:1749-1753. 2008
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. 19:746-751. 2008
A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. 18:1646-1651. 2007
Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. 18:1680-1684. 2007
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. 18:1177-1184. 2007
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. 18:116-121. 2007
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. 17:1749-1760. 2006
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. 17:1637-1643. 2006
Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing. 17:1090-1095. 2006
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG). 17:952-956. 2006
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. 17:334-340. 2006
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. 16:1688-1694. 2005
Communicating prognosis in cancer care: a systematic review of the literature. 16:1005-1053. 2005
Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. 16:735-742. 2005
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. 16:716-725. 2005
The difference between study recommendations, stated policy, and actual practice in a clinical trial. 15:1267-1273. 2004
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. 15:770-774. 2004
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. 15:665-670. 2004
Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. 14:1762-1767. 2003
ESMO takes a stand on supportive and palliative care. 14:1335-1337. 2003
Mammographic screening: case–control studies. 14:1190-1192. 2003
DNA methyltransferase inhibitors—state of the art. 13:1699-1716. 2002
Informing breast cancer patients about clinical trials:a randomized clinical trial of an educational booklet. 13:1414-1423. 2002
Malignant pleural mesothelioma: a phase II trial with docetaxel. 13:412-415. 2002
A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. 12:773-778. 2001
A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. 11:1579-1584. 2000
Attitudes towards and participation in randomised clinical trials in oncology: A review of the literature. 11:939-946. 2000
Cost-effectiveness analysis in oncology. 9:475-482. 1998
Searching the medical literature for the best evidence to solve clinical questions. 9:377-383. 1998
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. 9:217-219. 1998
Subcutaneous clodronate: A study evaluating efficacy in hypercalcemia of malignancy and local toxicity. 8:915-916. 1997
Radiation therapy following breast conservation surgery: Can it ever be avoided?. 8:217-218. 1997
On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993. 7:189-195. 1996
Duration of intravenous antibiotics for patients with neutropenic fever. 5:441-445. 1994
A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. 2:681-686. 1991

Annals of Oncology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)